Caladrius is developing cell therapy (CT) products that extract, expand and bolster a patient’s own (autologous) immune cells to treat diseases. CLBS03 is a potentially transformative Phase II candidate for recent-onset type I diabetes (TID), and CLBS14 and CLBS12 target ischemic injury conditions.

Continue reading

This version is programmatically created by Responsive Labs and qualified in its entirety to the original PDF.

Powered by Responsive Labs